AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC
Status:
Withdrawn
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
AMBER is a multicentre, single-arm phase II trial. The protocol treatment consists of of
sotorasib plus lenvatinib, as a second-line treatment. The primary objective of the trial is
to evaluate the clinical efficacy of sotorasib plus lenvatinib, in terms of objective
response rate, for patients with KRASG12C-mutant, metastatic NSCLC.